1205 related articles for article (PubMed ID: 30761123)
21. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation.
Romagnani C; Juelke K; Falco M; Morandi B; D'Agostino A; Costa R; Ratto G; Forte G; Carrega P; Lui G; Conte R; Strowig T; Moretta A; Münz C; Thiel A; Moretta L; Ferlazzo G
J Immunol; 2007 Apr; 178(8):4947-55. PubMed ID: 17404276
[TBL] [Abstract][Full Text] [Related]
22. Increased Peripheral NKG2A-NKG2D+CD3-CD16+CD56dim NK Cell Subset Was Positively Correlated with Antiphospholipid Antibodies in Patients of Obstetric Antiphospholipid Syndrome.
Zhang Y; Zhao Y; Si W; Yang B; Lin M; Zheng J; Cui L
Immunol Invest; 2022 Feb; 51(2):425-437. PubMed ID: 33103514
[TBL] [Abstract][Full Text] [Related]
23. NK cells and the profile of inflammatory cytokines in the peripheral blood of patients with advanced carcinomas.
Saito LM; Ortiz RC; Amôr NG; Lopes NM; Buzo RF; Garlet GP; Rodini CO
Cytokine; 2024 Feb; 174():156455. PubMed ID: 38043142
[TBL] [Abstract][Full Text] [Related]
24. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
25. Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.
Chalan P; Bijzet J; Kroesen BJ; Boots AM; Brouwer E
J Rheumatol; 2016 Jun; 43(6):1008-16. PubMed ID: 27036380
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
27. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic.
Ferlazzo G; Thomas D; Lin SL; Goodman K; Morandi B; Muller WA; Moretta A; Münz C
J Immunol; 2004 Feb; 172(3):1455-62. PubMed ID: 14734722
[TBL] [Abstract][Full Text] [Related]
28. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.
Wong JL; Mailliard RB; Moschos SJ; Edington H; Lotze MT; Kirkwood JM; Kalinski P
J Immunother; 2011 Apr; 34(3):270-8. PubMed ID: 21389871
[TBL] [Abstract][Full Text] [Related]
29. Expressions of natural cytotoxicity receptors and NKG2D on decidual natural killer cells in patients having spontaneous abortions.
Zhang Y; Zhao A; Wang X; Shi G; Jin H; Lin Q
Fertil Steril; 2008 Nov; 90(5):1931-7. PubMed ID: 18023431
[TBL] [Abstract][Full Text] [Related]
30. CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells.
Márquez ME; Millet C; Stekman H; Conesa A; Deglesne PA; Toro F; Sanctis JD; Blanca I
Cell Immunol; 2010; 264(1):86-92. PubMed ID: 20553754
[TBL] [Abstract][Full Text] [Related]
31. Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer.
Koo KC; Shim DH; Yang CM; Lee SB; Kim SM; Shin TY; Kim KH; Yoon HG; Rha KH; Lee JM; Hong SJ
PLoS One; 2013; 8(11):e78049. PubMed ID: 24223759
[TBL] [Abstract][Full Text] [Related]
32. Terminal Differentiation of CD56(dim)CD16(+) Natural Killer Cells Is Associated with Increase in Natural Killer Cell Frequencies After Antiretroviral Treatment in HIV-1 Infection.
Ahmad F; Tufa DM; Mishra N; Jacobs R; Schmidt RE
AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1206-12. PubMed ID: 26352913
[TBL] [Abstract][Full Text] [Related]
33. CD56
Ma M; Yin X; Zhao X; Guo C; Zhu X; Liu T; Yang M; Zhang Z; Fu Y; Liu J; Xu J; Ding H; Han X; Chu Z; Shang H; Jiang Y
J Leukoc Biol; 2019 Dec; 106(6):1313-1323. PubMed ID: 31483071
[TBL] [Abstract][Full Text] [Related]
34. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.
Béziat V; Duffy D; Quoc SN; Le Garff-Tavernier M; Decocq J; Combadière B; Debré P; Vieillard V
J Immunol; 2011 Jun; 186(12):6753-61. PubMed ID: 21555534
[TBL] [Abstract][Full Text] [Related]
35. New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression.
Pesce S; Squillario M; Greppi M; Loiacono F; Moretta L; Moretta A; Sivori S; Castagnola P; Barla A; Candiani S; Marcenaro E
Front Immunol; 2018; 9():2360. PubMed ID: 30374356
[TBL] [Abstract][Full Text] [Related]
36. Role of chemokines in the biology of natural killer cells.
Maghazachi AA
Curr Top Microbiol Immunol; 2010; 341():37-58. PubMed ID: 20369317
[TBL] [Abstract][Full Text] [Related]
37. Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation.
Tanaka J; Sugita J; Asanuma S; Arita K; Shono Y; Kikutchi M; Shiratori S; Wakasa K; Yasumoto A; Shigematu A; Kondo T; Kobayashi T; Asaka M; Imamura M
Hum Immunol; 2009 Sep; 70(9):701-5. PubMed ID: 19524005
[TBL] [Abstract][Full Text] [Related]
38. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
39. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation.
Dulphy N; Haas P; Busson M; Belhadj S; Peffault de Latour R; Robin M; Carmagnat M; Loiseau P; Tamouza R; Scieux C; Rabian C; Di Santo JP; Charron D; Janin A; Socié G; Toubert A
J Immunol; 2008 Aug; 181(3):2227-37. PubMed ID: 18641363
[TBL] [Abstract][Full Text] [Related]
40. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
